Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 … Next › Last »

FDA CMC Readiness Pilot: Sponsors Report Positive Experiences Despite Limited Early Uptake

September 12, 2025

Prevision Policy Clips | AZ’s FluMist DTC Ad Draws Cease-And-Desist Letter Signed By CBER Director Prasad

September 12, 2025

MAHA Strategy Includes Drug Approval “Improvements”; Pediatric Cancer Treatment Plans Are AI Test Cases, While NIH Would Take RWD Platform Lead

September 11, 2025

Prevision Policy Clips | “Hybrid” Pre-Approval Inspections Final Guidance Provides Clarification On Timelines

September 11, 2025

Non-Opioid Analgesics For Chronic Pain: Broad Label Could Be Supported By Combining Condition-Specific Indications, FDA Guidance Suggests

September 10, 2025

Prevision Policy Clips | Non-Opioid Chronic Pain Guidance Recommendations Include Superiority Trial Designs

September 10, 2025

HHS Seeks To Close Down DTC Ads By Strengthening Disclosure Rules: FDA Starts Campaign With Broad “Notice” Letters And 100 “Cease And Desist” Warnings

September 10, 2025

Preserving Placebos In Rare Disease Trials: FDA Showcases Flexibility During First “RISE” Meeting – But Makes Case That Placebo Controls Still Have A Place

September 9, 2025

Prevision Policy Clips | Former CBER OTP Deputy Director Rachel Anatol Joins Lilly

September 9, 2025

Prevision Policy Clips | Compounded GLP-1 Imports: FDA Launches “Green List”

September 8, 2025

Kennedy’s Vaccine Policies Face Bipartisan Pushback During Senate Hearing; Legacy Of “Operation Warp Speed” Could Be Vulnerability For HHS Secretary

September 5, 2025

Prevision Policy Clips | Senate Finance Committee Advances HHS General Counsel Nominee

September 5, 2025

“Real-Time” CRLs Are Here, As FDA Releases 34 Rejection Letters From 2025: Sponsors Will Need To Adjust Communication Plans; Replimune, Ultragenyx Letters Show Nuances

September 4, 2025

Prevision Policy Clips | Artificial Intelligence At FDA: E&C Health Ranking Member DeGette Calls For More Funding, Protocols

September 4, 2025

FDA “Plausible Mechanism” Pathway Will Be Limited To “Bespoke” Treatments, Prasad Tells Inaugural “RISE” Meeting; Harmonizing Toward CDER’s Historic Posture On Rare Disease?

September 3, 2025

FDA Launching Single-Trial Pathway For In-Born Error Treatments, Called “RDEP”; Sponsors, Agency Will Agree Up-Front On “Supportive Evidence” Plan

September 3, 2025

Prevision Policy Clips | HHS Touts "Real Time" Drug Price Information For Prescribers Under Final Rule

September 3, 2025

FDA Deadline Tracker: Path To 60 NME Approvals Looks Steep; Two Rejected, One Delayed In August; Only Four On September Calendar

September 2, 2025

Prevision Policy Clips | NIH Funding Would Be Flat Under House Appropriations Bill

September 2, 2025

FDA Proposes “Product-Agnostic” External Control For Rare Pediatric Brain Tumor DMG/DIPG As Potential Model For Other Oncology Registries

August 29, 2025

Prevision Policy Clips | CDC Acting Director Will Be HHS Deputy O’Neill

August 29, 2025

COVID Vaccine Updates: Sponsors Agree To Study Possible Link Between Vaccination And Long COVID Following Strain Update; CBER’s Prasad Suggests Goal Is Reassurance

August 28, 2025

Oncology Registries: FDA Eager To See Field Advance; August Workshop Is “Kick Off” For Longer Process

August 28, 2025

Prevision Policy Clips | CDC Leadership In Turmoil: HHS, White House Say CDC Director Monarez Has Been Fired

August 28, 2025

Prevision Policy Clips | FDA Neuroscience Office Changes: Laura Jawidzik Is Leading Division Of Neurology 2

August 27, 2025
1 2 3 4 5 … Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Copyright © 2025 Prevision Policy. All Rights Reserved. Privacy Policy